ClinicalTrials.gg
CompletedNCT07029698EASYVITUpdated Sep 4, 2026

A Study to See if a Combination of Vitamins That is Injected Into a Muscle is as Good and Safe as a Vitamin That is Taken by Mouth

A Phase 4 interventional study of Vitamin B12, Vitamin B6, Folic acid and Vitamin B12 (Cyanocobalamin) in Vitamin B12 Deficiency, sponsored by Medice Arzneimittel Pütter GmbH & Co KG. Completed at 2 sites in Ukraine. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Medice Arzneimittel Pütter GmbH & Co KG · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing Vitamin B 12 in Vitamin B 12 Deficiency — 1 open to participants now, 2 under way, 2 of them phase 3. Vitamin B 12 · Vitamin B 12 Deficiency.

Enrollment
10th of 14
46 · median 101
Started
2025
the only one that year
Phase 4
2 of 14
none open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Medice Arzneimittel Pütter GmbH & Co KG

Among the 14 studies testing Vitamin B 12 in Vitamin B 12 Deficiency, this one is the 10th largest by enrollment, is the only one that started in 2025, is one of 2 in phase 4, and was the 14th registered.

Vitamin B 12 Deficiency

73 studies on the registry are indexed under Vitamin B 12 Deficiency; 8 are open to participants now.

Browse Vitamin B 12 Deficiency studies →

Open to participants now

1 of the 14 studies testing Vitamin B 12 in Vitamin B 12 Deficiency is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Vitamin B 12

Vitamin B 12: first FDA approval 1947 (BEROCCA PN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2 Vitamin B 12 Deficiency studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Vitamin B 12 in Vitamin B 12 Deficiency, or all of them as a file.
02

Study summary

Primary efficacy objective:

To investigate the effects of a parenterally vitamin B12 combination treatment versus an oral vitamin B12 mono therapy on the vitamin B12 status in female and male patients as determined by the change from baseline in serum vitamin B12 concentration after 4 weeks (28 days) of treatment.

Secondary efficacy objectives:

To evaluate the effects of a parenterally vitamin B12 combination versus an oral vitamin B12 mono therapy after 4 weeks of treatment on:

  • Serum holotranscobalamin
  • Serum homocysteine
  • Serum methylmalonic acid
  • Combined vitamin B12 markers (cB12)
  • Serum folic acid
  • Serum vitamin B6
  • Serum S-adenosylmethione (SAM)
  • Serum S-adenosylhomocysteine (SAH)
  • SAM/SAH ratio
  • WHO-5 Well-Being Index
  • Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36)
  • Visual analogue scale (VAS) EQ-5D.

Safety objectives:

To evaluate the safety and tolerability of oral vitamin B12 mono therapy versus intramuscular vitamin B12 combination.

03

Conditions studied

  • Vitamin B12 Deficiency

Keywords

  • Vitamin B12 deficiency
  • Vitamin B12 status
  • methylation capacity
  • holotranscobalamin
  • homocysteine
  • methylmalonic acid
  • folic acid
  • vitamin B6
  • S-adenosylmethione
  • S-adenosylhomocysteine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written to participate in the study (according to Order of the Ministry of Health of Ukraine No. 690 (with amendments)).
  2. Female and male patients aged ≥18.
  3. Vitamin B12 deficiency, defined as serum vitamin B12 \< 350 pmol/L.
  4. Female patients of (WOCBP) must be using two acceptable methods of , (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc., with the exception of oral contraceptives), from the time of screening and for the duration of the study, through study completion and for 1 month following study completion. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. females must have had no regular menstrual bleeding for at least one (1) year prior to initial dosing. Female patients who report surgical sterilization must have had the procedure at least six (6) months prior to initial dosing. Surgical sterilization procedures should be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF. All female patients of childbearing potential must have negative pregnancy test results at screening. An additional pregnancy test will be performed on Days 0, 28, 56.
  5. Able to communicate well with the investigator and able to understand and comply with the requirements of the study.
  6. Patients are otherwise in relatively good health as determined by past medical history, physical examination, vital signs, and laboratory tests at screening (V -1).

Exclusion criteria

Exclusion Criteria:

  1. Active or recent vitamin B12, folic acid, B6 intake (the subject must not receive vitamin B12, folic acid, B6 drugs or food supplements for at least 6 months).
  2. Participation in a previous clinical study with vitamin B12 within the 6 months prior to screening.
  3. Any to one of the study drugs.
  4. Pregnant or nursing (lactating) women.
  5. Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
  6. Subjects with anemia ( \< 10 mg/dL) or significant neurological symptoms due to vitamin B12 deficiency.
  7. Any diseases that prevent intrinsic-factor independent passive diffusion in the small intestine (e.g. ileum resection)
  8. Current drug addiction and/or alcohol abuse as evidenced by patient history and/or as determined by the investigator at V-1.
  9. Cognitive or behavioural abnormalities that could impair the capacity to give or carry out protocol-specified procedures.
  10. Inability to take oral medication.
  11. Inability or unwillingness to comply with the study protocol.
  12. Previous (last 6 months) or current participation in another clinical study.
  13. Other medical, neuropsychiatric, or social conditions that, in the opinion of the investigator, are likely to adversely affect the risk-benefit of study participation, interfere with study compliance, or confound the study results.
  14. Subjects who are in a dependent relationship with the Investigator or the Sponsor.
  15. Subjects unwilling to give written informed consent to saving and/or propagation of anonymised medical data
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Vitamin injection

    1 injection twice weekly at the clinical site. Totally 8 injections through 4 week treatment period

    Drug: Vitamin B12, Vitamin B6, Folic acid

  • Active comparator
    Vitamin B12 tablet

    1 oral tablet once daily in the morning. Totally 28 tablets at approximately the same time each day through 4 week treatment period

    Drug: Vitamin B12 (Cyanocobalamin)

Interventions

06

What researchers measure

Primary outcomes

  1. Vitamin B12

    Effects of treatment on serum vitamin B12

    Time frame: Change from baseline at day 28

Secondary outcomes

  1. Holotranscobalamin

    Effects of treatment on serum holotranscobalamin

    Time frame: Change from baseline at day 28 and at follow up at day 56

  2. Homocystein

    Effects of treatment on serum homocystein

    Time frame: Change from baseline at day 28 and at follow up at day 56

  3. Methylmalonic acid

    Effects of treatment on serum methylmalonic acid

    Time frame: Change from baseline at day 28 and at follow up at day 56

  4. Combined vitamin B12 marker (cB12)

    Effects of treatment on cB12. Combined vitamin B12 markers (cB12) will be statistically calculated using the levels of Serum holotranscobalamin, Serum homocysteine, Serum methylmalonic acid. cB12 (cB12=log10\[(holoTC x B12)/(MMA x Hcy)\]-(age factor).

    Time frame: Change from baseline at day 28 and at follow up at day 56

  5. Serum S-adenosylmethione (SAM)

    Effects of treatment on serum S-adenosylmethione (SAM)

    Time frame: Change from baseline at day 28 and at follow up at day 56

  6. Serum S-adenosylhomocysteine (SAH)

    Effects of treatment on serum S-adenosylhomocysteine (SAH)

    Time frame: Change from baseline at day 28 and at follow up at day 56

  7. SAM/SAH ratio

    The change of the ratio will be assessed statistically using the levels of Serum S-adenosylmethione (SAM) and Serum S-adenosylhomocysteine (SAH)

    Time frame: Change from baseline at day 28 and at follow up at day 56

  8. Quality of life assessed with SF-36

    Effects of treatment on SF-36 questionnaire (from 0 to 100 points in each of the eight subscales, where the higher score means the higher quality of patient's life in each domain)

    Time frame: Change from baseline at day 28 and at follow up at day 56

  9. Quality of life assessed with WHO-5 questionnaire

    Effects of treatment on WHO-5 questionnaire (from 0 to 25, where the higher score means the higher quality of patient's life)

    Time frame: Change from baseline at day 28 and at follow up at day 56

  10. Quality of life assessed with VAS EQ-5D

    Effects of treatment on visual analogue scale EQ-5D (from 0 "the worst possible quality of life" to 10 "the best possible quality of life")

    Time frame: From baseline to day 28 and at follow up at day 56

Other outcomes

  1. Safety objectives

    The evaluation of safety will be conducted through a comprehensive analysis of adverse events.

    Time frame: assessed through 56 days of patient's participation

07

Study locations

2 sites
  • State institution "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine"
    Kharkiv, 61002, Ukraine
  • Private Enterprise Private Manufacturing Company "Acinus"
    Kropyvnytskyi, 25006, Ukraine
08

References and documents

Publications

  • Topp CW, Ostergaard SD, Sondergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167-76. doi: 10.1159/000376585. Epub 2015 Mar 28. PubMed 25831962 ↗
  • Naurath HJ, Riezler R, Putter S, Ubbink JB. Does a single vitamin B-supplementation induce functional vitamin B-deficiency? Clin Chem Lab Med. 2001 Aug;39(8):768-71. doi: 10.1515/CCLM.2001.128. PubMed 11592449 ↗
  • Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJ. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest. 1996 Jul 1;98(1):177-84. doi: 10.1172/JCI118763. PubMed 8690790 ↗
  • Fedosov SN, Brito A, Miller JW, Green R, Allen LH. Combined indicator of vitamin B12 status: modification for missing biomarkers and folate status and recommendations for revised cut-points. Clin Chem Lab Med. 2015 Jul;53(8):1215-25. doi: 10.1515/cclm-2014-0818. PubMed 25720072 ↗
  • Metaxas C, Mathis D, Jeger C, Hersberger KE, Arnet I, Walter P. Early biomarker response and patient preferences to oral and intramuscular vitamin B12 substitution in primary care: a randomised parallel-group trial. Swiss Med Wkly. 2017 Apr 7;147:w14421. doi: 10.4414/smw.2017.14421. eCollection 2017. PubMed 28421567 ↗
  • Smith AD, Warren MJ, Refsum H. Vitamin B12. Adv Food Nutr Res. 2018;83:215-279. doi: 10.1016/bs.afnr.2017.11.005. Epub 2018 Feb 2. PubMed 29477223 ↗
  • Conzade R, Koenig W, Heier M, Schneider A, Grill E, Peters A, Thorand B. Prevalence and Predictors of Subclinical Micronutrient Deficiency in German Older Adults: Results from the Population-Based KORA-Age Study. Nutrients. 2017 Nov 23;9(12):1276. doi: 10.3390/nu9121276. PubMed 29168737 ↗
  • 1. Vitamin B12 (Cobalamine). Referenzwerte für die Nährstoffzufuhr. Bonn, Deutsche Gesellschaft für Ernährung, Österreichische Gesellschaft für Ernährung, Schweizerische Gesellschaft für Ernährung (Hrsg.). 4. Aktualisierte Ausgabe 2018.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Oct 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2025
First posted
Jun 19, 2025
StartActual
Apr 16, 2025
Primary completionActual
Oct 7, 2025
CompletionActual
Oct 7, 2025
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07029698
Lead sponsor
Medice Arzneimittel Pütter GmbH & Co KG
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Apr 16, 2025
Primary completion
Oct 7, 2025
Completion
Oct 7, 2025
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vitamin B 12 · Vitamin B 6 · Pyridoxine · Folic Acid

Start the discussion